Join the fight against Alzheimer’s disease
People with Down syndrome often develop Alzheimer’s disease as they age. This disease leads to the accumulation of a protein called amyloid in the brain, as well as a progressive loss of cognitive abilities, such as memory loss, language, or orientation, among others.
The ABATE study is evaluating a vaccine against Alzheimer’s. We want to determine if the vaccine is safe. We also want to see if it delays the progression of Alzheimer’s disease in people with Down syndrome.
Who can participate in the ABATE study?
You may be able to participate in this study if you:
- Have Down syndrome
- Are between 35 and 50 years old
- Have a study partner
¿What is the treatment in the study?
The treatment in the study, ACI-24.060, is a new vaccine that is not yet on the market and could help eliminate the amyloid protein in the brain. This could slow down memory loss and cognitive problems.
In the ABATE study, which will last approximately 2 years, you will receive either the vaccine or an inactive vaccine (also called a placebo). This is done so that we can assess how the vaccine affects your body. Neither you nor the study team will know which vaccine you are receiving.
You will receive the vaccine or the inactive vaccine, as well as study tests and visits, completely free of charge.
If you would like to participate or receive more information, you can contact the study team by filling out the following form: